Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy

Abstract

Keywords

remdesivir anti-viral SARS-CoV-2 COVID-19

Get full access to this article

View all access options for this article.

References

Huang

Wang

, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.

Naveed

Uddin

Abdullah

, et al. Various evidence-based hypothetical and experimental treatment approaches and their effectiveness against COVID-19 worldwide: a comprehensive literature review. EMJO. 2020;4:265–285.

. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.

Khan

Karataş

Rahman

Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther. 2020:37(6):2575–2579.

Dong

Gao

. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.

Ferner

Aronson

. Remdesivir in Covid-19. BMJP Group. 2020:369:m1610.

Clinicaltrials.gov. Remdesivir | Covid-19. 2020.

Gordon

Tchesnokov

Feng

, et al. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem. 2020;295(15):4773–4779.

Elfiky

. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020;248:117477.

10.

Sheahan

Sims

Graham

, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9(393):eaa13653.

11.

Harrison

. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379–381.

12.

(EMA) EMA. Compassionate Use Opinions. European Medicine Agency; 2020.

13.

Wang

Cao

Zhang

, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271.

14.

Agostini

Andres

Sims

, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–18.

15.

De Clercq

. Therapeutic Options for the 2019 Novel Coronavirus (2019-nCoV). Nature Publishing Group; 2020.

16.

de Wit

Feldmann

Cronin

, et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection. Proc Nat Acad Sci USA. 2020;117(12):6771–6776.

17.

Holshue

DeBolt

Lindquist

, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–936.

18.

Grein

Ohmagari

Shin

, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.

19.

Wang

Zhang

, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10326):1569–1578.

20.

Beigel

Tomashek

Dodd

. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(10):994.

21.

Steve Holland

. U.S. emergency approval broadens use of Gilead’s COVID-19 drug remdesivir. US News & World Report. May 2020.

22.

Sternlicht

. Japan approves remdesivir for use On Severe COVID-19 Patients. Forbes. May 2020.

23.

Rajagopal

. Gilead sign licensing deal for remdesivir with three Indian companies. The Economic Times. May 2020.